Now Reading: Torrent Pharma Q2 net profit falls 10% to Rs 534 crore despite 51% revenue rise
-
01
Torrent Pharma Q2 net profit falls 10% to Rs 534 crore despite 51% revenue rise
Torrent Pharma Q2 net profit falls 10% to Rs 534 crore despite 51% revenue rise
The Story in Brief
Torrent Pharmaceuticals reported a 9.6% year-on-year decline in net profit to Rs 534 crore for the September quarter, even as revenue rose 50.8% to Rs 4,979 crore. The CNBC-TV18 poll estimate for net profit was Rs 544.3 crore and for revenue was Rs 4,905.6 crore.
The merger with JB Chemicals & Pharmaceuticals, effective July 8, 2026, had a temporary impact on revenue during the quarter, the company said. India revenue rose 20% to Rs 2,181 crore, outpacing market growth of 12%. Brazil revenue increased 38% to Rs 440 crore, US revenue grew 24% to Rs 417 crore, while Germany revenue fell 7% to Rs 283 crore.
For the first half of FY27, revenue rose 52.8% to Rs 9,900 crore, while net profit fell 3.4% to Rs 1,100 crore. Shares closed 2.78% lower at Rs 4,482 on the BSE on October 23.
Indian Opinion Analysis
Both CNBC-TV18 and The Hindu Business Line reported nearly identical figures for Torrent Pharma's Q2 results, with both noting the net profit decline and sharp revenue growth. CNBC-TV18 emphasised that net profit and EBITDA missed its poll estimates, framing the results as missing expectations. The Hindu Business Line focused on the revenue surge and margin improvement, without referencing poll misses. The uniform factual core is a profit drop alongside a revenue jump driven by the JB Chemicals merger, with integration costs cited as a temporary drag. The next concrete numbers to track are the company's progress on integration and Germany supply issues.
Coverage: 2 sources, 2 neutral
Sources (2): cnbctv18.com (neutral report), thehindubusinessline.com (neutral report)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
